231 filings
Page 4 of 12
POS AM
yjhl dz5c0tjtr2smi3p
13 Nov 20
Prospectus update (post-effective amendment)
5:03pm
8-K12G3
kh72vh9 3p
13 Nov 20
Notification of registration of securities
7:05am
8-K
x94skb yoyt54u
13 Nov 20
Results of Operations and Financial Condition
7:03am
EFFECT
8sglta iubngxcleeq
13 Nov 20
Notice of effectiveness
12:15am
S-4/A
nivo3o7w jv8
10 Nov 20
Registration of securities issued in business combination transactions (amended)
5:10pm
8-K
cojj17 2n
10 Nov 20
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
7:02am
CORRESP
ps2gubni784o
10 Nov 20
Correspondence with SEC
12:00am
8-K
j3byl40o
9 Nov 20
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
7:00am
8-K
lua48p5b4d x3ro8z3
29 Oct 20
Regulation FD Disclosure
4:03pm
8-K
brr 9fmatzii
13 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease
7:01am
8-K
nw7b751nu ororiscar3
9 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
7:00am
8-K
hkd9f3vw3un l3
8 Oct 20
Departure of Directors or Certain Officers
7:16am
UPLOAD
eunx5hctxlg5 ji83uz
8 Oct 20
Letter from SEC
12:00am
8-K
pwoqk89i7mauueusslo
6 Oct 20
Axovant Gene Therapies Announces Positive Six-month Follow-up Data from Second
7:14am
8-K
zh6d49ox f6
2 Oct 20
Other Events
5:19pm
424B5
3zpspa e4j
2 Oct 20
Prospectus supplement for primary offering
5:17pm
S-4
n0eo546xzt590
2 Oct 20
Registration of securities issued in business combination transactions
4:43pm
8-K
ygkx17053h1gfu
28 Sep 20
Submission of Matters to a Vote of Security Holders
4:56pm
DEFA14A
ueaneqv 545
12 Aug 20
Additional proxy soliciting materials
4:06pm